Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ).
Pharmaron Beijing Co., Ltd. has announced the composition of its board of directors and the roles within its board committees. The company has structured its board into executive, non-executive, and independent non-executive directors, with specific members assigned to various committees such as Audit, Remuneration and Appraisal, Nomination, and Strategy. This organizational update is likely to streamline decision-making processes and enhance corporate governance, potentially impacting the company’s strategic direction and stakeholder confidence.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a joint stock company incorporated in the People’s Republic of China. It operates within the pharmaceutical industry, focusing on providing a range of drug research and development services.
Average Trading Volume: 9,275,571
Technical Sentiment Signal: Buy
Current Market Cap: HK$42.55B
See more insights into 3759 stock on TipRanks’ Stock Analysis page.